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Abstract
Background In drug development, animal toxicology data
are very important for the evaluation of clinical safety. We
quantitatively assessed the safety profiles of blood cancer
drugs approved in Japan from category I (high) to V (low).
We examined the ratios of drug exposure in animals at the
no observed adverse effect level to those in humans at the
expected therapeutic dose. In addition, qualitative analysis
of the relationship between toxicological findings and
adverse drug reactions (ADRs) is one of the primary
approaches for determining the risk–benefit profile of a
pharmaceutical. This study thus aimed to evaluate the
potential of nonclinical safety assessments for predicting
ADRs in humans.
Methods We examined toxicological findings at the lowest
observed adverse effect level and ADRs in pivotal clinical
studies. We calculated concordance rates as the ratio of the
number of concordant ADRs to all ADRs.
Results Twenty-seven drugs were eligible for analysis.
Concordance rates ranged from 0 to 84.8%. No significant
differences were observed in concordance rates between
antibodies (median 14.3%) and small molecules (median
18.5%). There was a significant correlation between
concordance rates and quantitative safety profiles
(p = 0.047), suggesting that some drugs with low safety
profiles (categories III, IV, or V) have high concordance
rates.
Conclusion The results suggested that ADRs in clinical
trials could be predicted based on toxicity data obtained in
animal tests, especially for some drugs with a low quan-
titative safety profile.
Key Points
Qualitative analysis of the relationship between
toxicological findings and adverse drug reactions
(ADRs) is one of the primary measures for determining
the risk–benefit profile of a pharmaceutical.
We evaluated the potential of nonclinical safety
assessments for predicting ADRs in humans on blood
cancer drugs approved in Japan.
The results suggested that ADRs in clinical trials could
be predicted on the basis of toxicity data obtained in
animal tests.
1 Introduction
Nonclinical data play a fundamental role in new drug
development; they can be used to assess potential safety
risks. The International Conference on Harmonisation
(ICH) M3(R2) recommends that nonclinical safety studies
should be adequate to characterize potential adverse effects
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that might occur under the conditions of the clinical trial to
be supported [1]. It also states that clinical trials defined by
ICH E8 should be extended based on the demonstration of
adequate safety in previous clinical trial(s), as well as on
additional nonclinical safety information [1, 2]. Human
pharmacology studies with biomarkers conducted at the
early clinical phases do not play a key role for safety
estimation in therapeutic exploratory and/or therapeutic
confirmatory studies in Japanese new drug applica-
tions (NDAs) [3]; therefore, animal toxicology data are
useful for the prediction of safety profiles during the late
clinical phases.
As one of the primary measures for determining the
risk–benefit profile of a pharmaceutical, we recently con-
ducted a study to evaluate the quantitative safety profiles of
blood cancer drugs approved in Japan [4]. We examined
safety indices obtained using the ratio of drug dose/expo-
sure in animals at the no observed adverse effect level
(NOAEL) to that in humans at the expected therapeutic
dose. We used data from toxicokinetic studies indispens-
able for safety assessment as stated in ICH S3A [5]. We
categorized quantitative safety profiles into five types, from
I (high) to V (low), and found that although there were
some drugs for blood cancer treatment with low quantita-
tive safety profiles (categories III, IV, and V), the safety
profiles of those drugs were not discussed in the NDA
dossiers [4]. In the regulatory reviews for drug approval,
quantitative safety profiles can provide a certain amount of
information for the evaluation of the risk–benefit balance.
In addition, it is important to assess drug safety using
qualitative aspects by comparing nonclinical toxicology
findings and adverse drug reactions (ADRs). However,
there have been relatively few attempts to methodically
assess the correlation between toxicity levels caused by the
same drugs in animals and humans.
Igarashi et al., at the Japanese Pharmaceutical Manu-
facturers Association (JPMA), investigated published
papers on general pharmacological studies and the clinical
adverse reactions observed during new drug development
[6]. They demonstrated that tests of cardiovascular func-
tions, spontaneous locomotor activity, and intestinal
transport are of considerable value in predicting ADRs.
Furthermore, Olson et al. revealed that 71% of ADRs were
observed in animals for the same target organ and the
hematological, gastrointestinal, and cardiovascular ADRs
were highly concordant [7]. However, evidence supporting
the prediction of or extrapolation to human toxicities from
the results of animal toxicology studies is scarce, and there
is no consensus on this matter. Against this background,
our primary objective in this study was to evaluate the
potential of nonclinical safety assessments for predicting
ADRs in humans treated with blood cancer drugs.
2 Methods
2.1 Data Source
We first reviewed data from drugs for blood cancer because
severe adverse reactions were observed during clinical
development and post-marketing surveillance of anticancer
drugs. Moreover, the number of new molecular enti-
ties (NMEs) in this therapeutic area was suitable for this
examination as a starting point and this group contained not
only small-molecule drugs but also macromolecular drugs
such as antibody drugs. Drugs for blood cancer approved in
Japan from September 1999 to November 2016 as NMEs
were analyzed. NOAEL, maximum approved dose, expo-
sure levels at NOAEL and maximum approved dose,
lowest observed adverse effect level (LOAEL), toxico-
logical findings obtained at LOAEL, and ADRs were
extracted from NDA review reports by the Ministry of
Health, Labor and Welfare (MHLW) (until March 2004),
the Pharmaceuticals and Medical Devices Agen-
cy (PMDA) (from April 2004), the common technical
document (CTD) [8] by marketing authorization holders,
package inserts, and interview forms available on the
PMDA website [27]. Data were obtained in accordance
with Japanese domestic regulations such as Good Clinical
Practice [9] and Good Laboratory Practice [10] guidelines
complying with the Pharmaceutical Affairs Law. Of the
539 NMEs identified, 28 drugs for blood cancer were
identified for analysis (Table 1).
2.2 Data Handling
2.2.1 Safety Index
Safety indices are obtained from the ratio of doses and
exposure levels in animals to those in humans. The safety
index by dose (SI-D), safety index by maximum plasma
Table 1 NMEs for blood cancer analyzed in this study
Alemtuzumab Anagrelide hydrochloride hydrate Azacitidine
Bendamustine hydrochloride Bexarotene Bortezomib
Bosutinib Brentuximab vedotin Cladribine
Clofarabine Dasatinib hydrate Fludarabine phosphate
Gemtuzumab ozogamicin Ibritumomab tiuxetan Ibrutinib
Imatinib mesylate Lenalidomide hydrate Mogamulizumab
Nelarabine Nilotinib hydrochloride hydrate Ofatumumab
Panobinostat lactate Pomalidomide Rituximab
Ruxolitinib phosphate Tamibarotene Thalidomide
Vorinostat
NMEs new molecular entities
134 S. Kubota et al.
concentration (Cmax) [SI-C], and safety index by area under
the plasma concentration–time curve (AUC) [SI-A] were
calculated according to the following equations [4].
SI-D = NOAEL (mg/kg/day)/maximum approved dose
(mg/kg/day)
SI-C = Cmax at NOAEL (lg/mL)/Cmax at maximum
approved dose (lg/mL)
SI-A = AUC at NOAEL (lgh/mL)/AUC at maximum
approved dose (lgh/mL).
2.2.2 Quantitative Safety Profile
The quantitative safety profile of each drug was assessed if
both SI-D and SI-C or SI-A were available. The safety
profiles fell into five categories based on the safety indices
(Fig. 1): profile 1, SI-D[1.0 and SI-C or SI-A[1.0; profile
II, SI-D &1.0 and SI-C or SI-A &1.0; profile III, SI-D
[1.0 and SI-C or SI-A\1.0; profile IV, SI-D\1.0 and SI-
C or SI-A[1.0; and profile V, SI-D\1.0 and SI-C or SI-A
\1.0 [4].
These categories comprise one approach to clarify safety
characteristics including the balance between safety index
by dose and that by exposure. Safety profile I shows that
both dose and exposure levels for animals exceed those for
humans; therefore, it is interpreted that there is a certain
safety margin for a drug categorized in safety profile I,
while a drug in safety profile V has no safety margin for
either dose or exposure levels.
2.2.3 Collection of Nonclinical Toxicological Findings
and ADRs
2.2.3.1 Drugs for Which Toxicological Findings at LOAEL
Are Available Nonclinical toxicological findings at
LOAEL for each drug were collected from the same non-
clinical study mentioned in our previous report [4], that is,
the study that gave the smallest NOAEL. To compare the
toxicological findings with ADRs, names and the number
of ADRs of Cgrade 3 were obtained from the clinical
studies defined as pivotal. The grades were based on
National Cancer Institute—Common Toxicity Criteria
Version 2.0 [11], Common Terminology Criteria for
Adverse Events (CTCAE) Version 3.0 [12], and CTCAE
Version 4.0 [13]. In cases where the grades of severity
were categorized as mild, moderate, and severe, the severe
grade was considered to be Cgrade 3. Prioritization of
pivotal studies used for analysis is shown in Table 2. We
placed the utmost importance on studies with Japanese
patients. If phase III data of Japanese patients were not
obtained, phase II studies with Japanese patients were
selected. In the case that no Japanese patient data were
available other than a phase I study, foreign clinical data
for which extrapolation to the Japanese population had
been accepted based on ICH E5 [14] were used. As there
was one drug (gemtuzumab ozogamicin) for which ADRs
were not available in the source documents, adverse events
(AEs) were substituted for ADRs.
Animal Human 
NOAEL 
Maximum approved dose 
Animal  Human 
Exposure at NOAEL     
Exposure at Maximum approved dose 
Dose level Exposure level I 
Animal Human Animal  Human 
II 
Animal Human Animal  Human 
III 
Animal Human Animal  Human 
V 
Dose level Exposure level 
Dose level Exposure level 
Dose level Exposure level 
Animal Human Animal  Human 
IV Dose level Exposure level 
Fig. 1 Quantitative safety
profile. NOAEL no observed
adverse effect level
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2.2.3.2 Drugs for Which Toxicological Findings at LOAEL
Are Not Available If no toxicological study at a dose over
NOAEL had been performed and toxicological findings at
LOAEL were not available, nontoxic observations at
NOAEL were collected. However, because observations at
NOAEL were not considered as toxicity changes, it is not
appropriate to compare such data with ADRs with a severe
grade. For such drugs, clinical ADRs Bgrade 1 were taken
for comparison.
2.2.4 Concordance of ADRs and Toxicological Findings
An ADR reported in a clinical study was considered con-
cordant with a nonclinical toxicological finding when the
same finding was made in a human and an animal, or
similar observations were made for similar organs
[6, 7, 15, 16] (Table 3). Concordance rate was calculated as
follows:
2.2.4.1 Drugs for Which Toxicological Findings at LOAEL
Are Available Concordance rate (%) = (number of
ADRs or AEs of Cgrade 3 that are concordant with toxi-
cological findings at LOAEL/total number of ADRs or AEs
of Cgrade 3) 9 100.
2.2.4.2 Drugs for Which Toxicological Findings at LOAEL
Are Not Available Concordance rate (%) = (number of
ADRs or AEs of Bgrade 1 that are concordant with non-
toxic observations at NOAEL/total number of ADRs or
AEs of Bgrade 1) 9 100.
2.3 Statistical Analysis
The SPSS software Version 23 (IBM, Armonk, NY, USA)
was used to perform statistical analysis of the collected
data. Comparisons were performed by the Mann–Whitney
U test. Regarding the association between two variables
measured on at least an ordinal scale, the Spearman rank-
order correlation coefficient was used. A p value of\0.05
was considered statistically significant.
3 Results
Of the 28 drugs for blood cancer, 27 were eligible for
analysis. Ibritumomab tiuxetan was excluded because the
lack of data prevented calculation of the safety index.
NOAEL, LOAEL, and clinical studies selected for the
analysis are listed in Table 4. Table 5 shows the con-
cordance rate, administration route, drug type, species,
and quantitative safety profile for each drug. The con-
cordance rate of bosutinib was not calculated because of
the lack of information on the severity of ADRs. The
concordance rate of each System Organ Class (SOC)
categorized by CTCAE is listed in Table 6. ADRs that
were concordant with nonclinical observations in blood
lymphatic system disorders and investigations were
observed for many drugs, that is, 16 and 15 out of 26
drugs, respectively.
The mean concordance rate of 26 drugs excluding
bosutinib was 23.9% (median: 18.5%), with a range of
0–84.8%. When stratified by the drug type, the mean
concordance rates of small-molecule drugs and antibody
drugs were 24.1% (median 18.5%) and 23.3% (median
14.3%), respectively. There was no significant difference
between them (p = 0.839; Fig. 2). The mean concor-
dance rates of drugs with nonclinical data for rodents,
non-rodents, oral drugs, and injectable drugs were 24.7%
(median 24.3%), 23.6% (median 16.7%), 16.4% (median:
6.8%), and 31.4% (median 21.8%), respectively
(Table 5). No significant differences between concor-
dance rates were observed based on species (rodent vs.
non-rodent; p = 0.935) and administration route
(p = 0.169).
The mean concordance rates of drugs excluding bosu-
tinib by quantitative safety profile [five types; from I (high)
to V (low)] were 7.4% (I), 18.4% (III), and 37.0%
(V) (Table 5). (No drug was categorized into II in this
study. Bosutinib was categorized into IV, but its concor-
dance rate was not calculable.) The concordance rate and
quantitative safety profile were weakly correlated (Spear-
man’s r = 0.448, p = 0.047; Fig. 3).
Table 2 Handling of pivotal studies
Priority Clinical study
1 The Japanese phase III study submitted as formal
documents
2 The Japanese phase II study submitted as formal documents
3 Phase II data from the Japanese phase I/II study submitted
as formal documents
4 The Japanese phase I/II study submitted as formal
documents, if the number of events of each ADR was not
counted by phase I and II separately
5 Multi-regional phase III study including Japan submitted as
formal documents
6 Multi-regional phase II study including Japan submitted as
formal documents
7 Foreign phase III study submitted as formal documentsa
8 Foreign phase II study submitted as formal documentsa
ADR adverse drug reaction
a If there were two or more studies, the study with the largest number
of subjects was selected
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Table 3 Toxicological findings
in animals considered
concordant with ADRs in
humans
ADRs Concordant toxicological findings in animals
Infections and infestations
Neutropenic infection Neutrophil count;
Blood and lymphatic system disorders
Erythropenia RBC count;, reticulocyte count;





Anemia Hematocrit;, hemoglobin content;
Metabolism and nutrition disorders




Musculoskeletal, and connective tissue disorders
Intracranial hemorrhage Bleeding in the brain
Gastrointestinal disorders
Constipation Abnormal feces, feces;, no feces
Vomiting Vomit
Diarrhea Soft feces, diarrhea
Gastritis Hemorrhage in gastric mucosa
Bleeding peptic ulcer Hemorrhage in gastric mucosa
Skin and subcutaneous tissue disorders
Rash Rash in hind limb skin





Decrease in hematocrit Decrease in hematocrit level
Decrease in hemoglobin Decrease in hemoglobin, decrease in hemoglobin level
Decrease in phosphorus blood level Decrease in phosphorus
Decrease in blood potassium level Potassium;
Decrease in CD4 lymphocytes Lymphocytes;
Lymphocyte count decreased Lymphocytes;
WBC count; WBC count;, cell density of bone marrow;
Body weight; Body weight;
RBC count; RBC count;
Reticulocyte count decreased RBC count;
Platelet count decreased Platelet count;, cell density of bone marrow;
Neutropenia Neutrophils;
Increase in alanine aminotransferase Alanine aminotransferase:
Decrease in blood albumin level Blood albumin;
Decrease in alkaline phosphatase Alkaline phosphatase;
Transaminases increased Aspartate aminotransferase:
Increase in gamma-glutamyl transpeptidase Gamma-glutamyl transpeptidase:
ADRs adverse drug reactions, RBC red blood cell, WBC white blood cell, : increased, ; decreased
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Table 4 NOAEL, LOAEL, and pivotal studies
Drug NOAEL and LOAEL in the most sensitive
speciesa (mg/kg/day)
Pivotal studies
NOAEL LOAEL Study Title Priority
numberc
Alemtuzumab ND 3.0 14- or 30-day repeated-
dose toxicity study in
monkeys
A phase III study to evaluate the efficacy and safety of front-line
therapy with alemtuzumab (Campath, MabCampath) vs.






0.3 3.0 1-month repeated-dose
toxicity study in dogs
A phase III, open-label, single-arm study evaluating the effect of
SPD422 on platelet lowering and safety in Japanese adults
with at risk essential thrombocythemia who are intolerant or
refractory to current cytoreductive treatment
1
Azacitidine 0.2 0.4 2-week repeated-dose
toxicity study in dogs





1.65 3.3 15-week repeated-dose
toxicity study in dogs
An integration analysis of phase I study of SyB L-0501in patients
with low-grade B-cell non-Hodgkin lymphoma and phase II
study of SyB L-0501 in patients with low-grade B-cell non-
Hodgkin lymphoma and mantle cell lymphoma
4
Bexarotene 1.0 3.0 39-week repeated-dose
toxicity study in dogs
A phase I/II study of Tagretin capsules (BSC-1) in Japanese
patients with refractory cutaneous T-cell lymphoma
4
Bortezomib 0.045 0.067 4-week repeated-dose
toxicity study in
monkeys
An international, multi-center, randomized, open-label study of
PS-341 vs. high-dose dexamethasone in patients with relapsed
or refractory multiple myeloma
7
Bosutinib 5.0 NAb 1-month repeated-dose
toxicity study in dogs
A phase I/II study of SKI-606 administered as a single agent in





0.5 5.0 4-week repeated dose
toxicity study in rats
A phase I/II, single-arm, open-label study of SGN-35 in Japanese
patients with relapsed refractory CD30-positive Hodgkin
lymphoma or systemic anaplastic large-cell lymphoma
4
Cladribine 0.1 0.3 2-week repeated-dose
toxicity study in
monkeys
A phase II study in patients with hairy cell leukemia 2
Clofarabine 0.375 0.75 6-month repeated-dose
toxicity study in dogs
A phase II open-label study of clofarabine in pediatric patients




0.9 15 1-month repeated-dose
toxicity study in rats
A phase I/II study of BMS-354825 in patients with chronic phase
Philadelphia chromosome-positive chronic myeloid leukemia




1 10 13-week repeated-dose
toxicity study in dogs
A phase II study in patients with chronic lymphatic leukemia 2
Gemtuzumab
ozogamicin
0.12 0.47 4-week repeated-dose
toxicity study in rats
A phase II study in patients with initial relapse CD33-positive
acute myelocytic leukemia
8
Ibrutinib 12 36 2-week repeated-dose
toxicity study in rats
A randomized, multicenter, open-label, phase III study of
Bruton’s tyrosome kinase inhibitor ibrutinib vs. ofatumumab in





3 10 13-week repeated-dose
toxicity study in dogs





2 4 52-week repeated-dose
toxicity study in
monkeys
A multicenter, randomized, parallel-group, double-blind,
placebo-controlled study of CC-5013 plus dexamethasone vs.
dexamethasone alone in previously treated subjects with
multiple myeloma
7
Mogamulizumab 40 NAb 13-week repeated-dose
toxicity study in
monkeys
An open-label, uncontrolled study in patients with recurrent or
relapsed CCR4-positive Adult T-cell leukemia
2
Nelarabine 10 20 30-day repeated dose
toxicity study in
monkeys
A phase II study of nelarabine (506U78) in patients with
refractory or relapsed T-lineage acute lymphoblastic leukemia
or lymphoblastic lymphoma
8
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4 Discussion
The purpose of our study was to analyze the potential of
nonclinical safety assessments in predicting ADRs in
humans. We obtained the nonclinical toxicological findings
and ADRs observed in clinical trials for each drug and
examined the relationship of safety levels for animals and
humans by calculating the concordance rates. In similar
studies, the JPMA conducted systematic and retrospective
surveys to analyze the concordance of toxicity in animal
tests and ADRs in clinical trials [15, 16]. Igarashi et al.
investigated 141 drugs approved in Japan [6]. They showed
that general pharmacological studies of cardiovascular
functions, spontaneous locomotor activity, and intestinal
transport were useful in predicting ADRs [6]. More
recently, Tamaki et al. conducted a study to examine the
usefulness of nonclinical safety assessments in predicting
ADRs in humans [17]. They revealed that 37% of ADRs
were predictable based on concordant toxicological find-
ings in animals [17]. This figure is slightly higher than the
mean concordance rate of our study (23.9%). However,
considering that they targeted all drugs, excluding anti-
cancer agents and vaccines, and collected ADRs with an
incidence rate of C5%, these figures are comparable.
In a further investigation, we analyzed the correlation
between the concordance rate and the quantitative safety
profile obtained in our previous study [4]. As shown in
Fig. 3, there was a significant correlation between these
Table 4 continued
Drug NOAEL and LOAEL in the most sensitive
speciesa (mg/kg/day)
Pivotal studies





5 15 4-week repeated-dose
toxicity study in dogs
A phase IA/II multicenter, dose-escalation study of oral
AMN107 on a continuous daily dosing schedule in adult
patients with Glivec (imatinib)-resistant/intolerant chronic
myeloid leukemia in chronic or accelerated phase or blast
crisis, relapse/refractory Ph ? A ??, and other hematologic
malignancies (CAMN1072101 phase II component)
3
Ofatumumab 100 NAb 7-month repeated-dose
toxicity study in
monkeys
A single-arm, international, multi-center trial of HuMax-CD20, a
fully human monoclonal anti-CD20 antibody, in patients with





0.15 0.5 39-week repeated-dose
toxicity study in dogs
A multicenter, randomized, double-blind, placebo-controlled
phase III study of panobinostat in combination with bortezomib
and dexamethasone in patients with relapsed multiple myeloma
5
Pomalidomide 0.1 1 9-month repeated-dose
toxicity study in
monkeys
A phase II, multicenter, single-arm, open-label study in Japan to
evaluate the efficacy and safety of pomalidomide (CC-4047) in
combination with dexamethasone in subjects with relapsed and
refractory multiple myeloma
2
Rituximab 20 NAb 2-month repeated-dose
toxicity study in
monkeys
A phase II, repeated-dose study of IDEC-C2B8 in patients with





0.1 1 9-month repeated-dose
toxicity study in
monkeys
A multi-national, open-label, phase II study of the JAK inhibitor
INC424 in patients with primary myelofibrosis, post-
polycythemia vera myelofibrosis, or post-essential
thrombocythemia myelofibrosis
6
Tamibarotene 0.016 0.08 4-week repeated-dose
toxicity study in rats
A late phase II study in patients with acute promyelocytic
leukemia
2
Thalidomide 30 300 13-week repeated-dose
toxicity study in rats
A multi-center, open-label, dose-escalation study in patients with
multiple myeloma relapsing after hematopoietic stem cell
transplantation or with chemotherapy-resistant multiple
myeloma
2
Vorinostat 20 50 4-week repeated-dose
toxicity study in rats
A phase IIb multicenter clinical trial of oral suberoylanilide
hydroxamic acid in advanced cutaneous T-cell lymphoma
8
JAK janus kinase, LOAEL lowest observed adverse effect level, NA not available, ND not detected, NOAEL no observed adverse effect level
a Animal species that gives the smallest NOAEL
b Dose over NOAEL was not investigated
c Refer to Table 2
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Table 5 Concordance rate, administration route, drug type, and quantitative safety profile
Drug Concordance rate (%) Administration route Drug type Speciesa Quantitative safety
profile (SI-Db, SI-Cc, SI-Ad)
Alemtuzumab 34.3e Injection Antibody Monkey NA (NA, NA, NA)
Anagrelide Hydrochloride hydrate 0e Oral SM Dog III ([1.0,\1.0,\1.0)
Azacitidine 84.8e Injection SM Dog V (\1.0,\1.0,\1.0)
Bendamustine hydrochloride 65.0e Injection SM Dog V (\1.0, NA,\1.0)
Bexarotene 0e Oral SM Dog V (\1.0,\1.0,\1.0)
Bortezomib 13.0e Injection SM Monkey NA ([1.0, NA, NA)
Bosutinib NA Oral SM Dog IV (\1.0,[1.0,[1.0)
Brentuximab Vedotin 76.2e Injection Antibody Rat V (\1.0,\1.0, NA)
Cladribine 28.0e Injection SM Monkey NA ([1.0, NA, NA)
Clofarabine 17.9e Injection SM Dog V (\1.0,\1.0,\1.0)
Dasatinib hydrate 26.7e Oral SM Rat V (\1.0,\1.0,\1.0)
Fludarabine phosphate 15.4e Injection SM Dog NA ([1.0, NA, NA)
Gemtuzumab ozogamicin 21.8e Injection Antibody Rat V (\1.0,\1.0, NA)
Ibrutinib 2.1e Oral SM Rat NA ([1.0, NA, NA)
Imatinib mesilate 50.0e Oral SM Dog V (\1.0,\1.0,\1.0)
Lenalidomide hydrate 22.1e Oral SM Monkey I ([1.0,[1.0,[1.0)
Mogamulizumab 6.8f Injection Antibody Monkey I ([1.0, NA,[1.0)
Nelarabine 44.4e Injection SM Monkey V (\1.0, NA,\1.0)
Nilotinib Hydrochloride hydrate 1.2e Oral SM Dog V (\1.0,\1.0,\1.0)
Ofatumumab 0.7f Injection Antibody Monkey I ([1.0,[1.0,[1.0)
Panobinostat Lactate 19.1e Oral SM Dog V (\1.0,\1.0,\1.0)
Pomalidomide 6.8e Oral SM Monkey III ([1.0,\1.0,\1.0)
Rituximab 0f Injection Antibody Monkey III ([1.0,\1.0, NA)
Ruxolitinib Phosphate 48.6e Oral SM Dog III ([1.0,\1.0,\1.0)
Tamibarotene 0e Oral SM Rat NA (\1.0, NA, NA)
Thalidomide 0e Oral SM Rat I ([1.0,[1.0,[1.0)
Vorinostat 36.8e Oral SM Rat III ([1.0, NA,\1.0)
Concordance rate (%) All Drug type Administration route Species Quantitative safety profile
SM Antibody Injection Oral Rodents Non-rodents I II III IV V
ng 26 20 6 13 13 7 19 4 0 5 0 11
Range 0–84.8 0–84.8 0–76.2 0–84.8 0–50.1 0–76.2 0–84.8 0–22.1 0–48.6 0–84.8
















Median 18.5 18.5 14.3 21.8 6.8 24.3 16.7 3.8 6.8 26.7
ADRs adverse drug reactions, AEs adverse events, AUC area under the plasma concentration–time curve, Cmax maximum plasma concentration, NA
not available, NOAEL no observed adverse effect level, SD standard deviation, SM small molecule
a Animal species that gives the smallest NOAEL
b SI-D = NOAEL (mg/kg/day)/the maximum approved dose (mg/kg/day)
c SI-C = Cmax at NOAEL (lg/mL)/Cmax at the maximum approved dose (lg/mL)
d SI-A = AUC at NOAEL (lgh/mL)/AUC at the maximum approved dose (lgh/mL)
e Concordance rate (%) = (number of ADRs or AEs of Cgrade 3 that are concordant with toxicological findings at LOAEL/total number of ADRs
or AEs of Cgrade 3) 9 100
f Concordance rate (%) = (number of ADRs or AEs of Bgrade 1 that are concordant with nontoxic observations at NOAEL/total number of ADRs
or AEs of Bgrade 1) 9 100
g Excluding bosutinib
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Table 6 Concordance rate of
each System Organ Class
categorized by CTCAE
System Organ Classa (drug) A B C D E F G H Total (%)
Alemtuzumab 34.3 34.3
Anagrelide hydrochloride hydrate 0
Azacitidine 0.7 59.9 0.7 0.3 23.2 84.8
Bendamustine hydrochloride 2.1 0.7 11.0 61.1 65.0
Bexarotene 0
Bortezomib 7.3 1.8 3.1 0.9 13.0
Bosutinib NA
Brentuximab vedotin 76.2 76.2
Cladribine 28.0 28.0
Clofarabine 6.0 2.6 6.0 3.4 18.0
Dasatinib hydrate 6.2 20.5 26.7
Fludarabine phosphate 15.4 15.4
Gemtuzumab ozogamicin 9.1 0.3 12.4 21.8
Ibrutinib 2.1 2.1
Imatinib mesylate 4.8 45.2 50.0
Lenalidomide hydrate 13.5 0.2 1.3 0.2 5.2 1.7 22.1
Mogamulizumab 6.8 6.8
Nelarabine 44.4 44.4
Nilotinib hydrochloride hydrate 1.2 1.2
Ofatumumab 0.7 0.7
Panobinostat lactate 16.6 2.5 19.1
Pomalidomide 4.5 2.3 6.8
Rituximab 0
Ruxolitinib phosphate 46.8 1.8 48.6
Tamibarotene 0
Thalidomide 0
Vorinostat 21.1 10.5 5.3 36.9
CTCAE Common Terminology Criteria for Adverse Events, NA not available
a System Organ Class: A: Infections and infestations; B: Blood and lymphatic system disorders; C:
Metabolism and nutrition disorders; D: Gastrointestinal disorders; E: Skin and subcutaneous tissue disor-
ders; F: Musculoskeletal, and connective tissue disorders; G: General disorders and administration site
conditions; H: Investigations






All            Small molecule     Anbody 
n                         26                20                   6 
Mean (SD)    23.9 (24.8)                    24.1(24.2)      23.3(29.1)              
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Mean SD 
Fig. 2 Concordance rates of all, small-molecule, and antibody drugs.
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Fig. 3 Correlation between concordance rate and quantitative safety
profile
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two factors. As the concordance rate varied over a wide
range, from 0 to 84.8%, it was difficult to predict clinical
ADRs in a comprehensive manner based on animal toxi-
cological findings. However, a significant correlation
between the concordance rate and the quantitative safety
profile indicated that drugs with a low quantitative safety
profile would show relatively high concordance rates.
Examination of animal toxicological findings, especially
for drugs with a low quantitative safety profile, has the
potential to predict their clinical safety. For drugs with the
quantitative safety profile of category III, IV, or V, the dose
and/or exposure at clinical therapeutic use exceeded the
dose/exposure at NOAEL. Therefore, some animal toxi-
cological findings at LOAEL for such drugs might be
reproducible in clinical use. If the toxicological finding at
LOAEL is not available, the observations at NOAEL might
provide useful information and help to predict ADRs to
some extent. However, considering that the mean concor-
dance rates of drugs with a high quantitative safety profile
(category I: 7.4%) were lower than those of drugs with a
low safety profile (category III: 18.4%, or category V:
37.0%), the overall risk–benefit of those drugs should be
carefully considered, taking into account various aspects.
When looking at concordance rates by SOC, ADRs con-
cordant with nonclinical observations in blood and lym-
phatic system disorders and investigations were found for
approximately 60% of the drugs in this study. In terms of
blood cancer drugs, toxicological findings related to those
SOCs might provide beneficial information to predict
clinical ADRs in those SOCs.
We found that the median concordance rate of antibody
drugs (14.3%) was lower than that of small-molecule drugs
(18.5%), although there was no significant difference
between them and the number of antibodies was small.
Tamaki et al. reported that the proportion of correlated
ADRs in small-molecule drugs was 46% and that in anti-
body drugs was 16%, indicating a trend similar to that of
our results [17]. For small molecules, general toxicology
tests are usually performed in rodents and non-rodents
(ICH S9) [18]. However, ICH S6 [19] states that safety
evaluation programs for biotechnology-derived pharma-
ceuticals should normally include two relevant species, but
in certain justified cases, one relevant species may suffice.
According to the ICH S6 guideline, the animal species for
testing of monoclonal antibodies are those that express the
desired epitope and demonstrate a similar tissue cross-re-
activity profile as for human tissues.
In our study, four of the six antibody drugs had non-
clinical data only for monkeys, and other species were not
investigated. This might have contributed to the low con-
cordance rate. Chapman et al. discussed the selection of
species for toxicology studies of monoclonal antibodies
[20]. They raised the concern that species cross-reactivity
alone might not be sufficient to confirm species suitability.
They referred to the case of TGN412, an anti-CD28 super-
agonist monoclonal antibody, which induced a life-threat-
ening cytokine storm in its first human study. Although
there was no significant difference in concordance rates
between antibody and small-molecule drugs, an appropriate
way to predict the risk to humans, based on nonclinical
toxicity findings for antibody drugs, is still needed. In 2014,
seven of the top ten best-selling drugs in the world were
biotechnology-derived pharmaceuticals [21] and many
more biopharmaceutical products are under development
[22]. Therefore, practical guidance for a risk–benefit
assessment of biopharmaceuticals would be beneficial.
There is currently no established method to weigh the
predictability of ADRs in humans on the basis of animal
data. Bailey et al. conducted several studies on human drug
safety using toxicity data obtained from animal tests
[23–25]. They suggested that toxicity observed in animals
occurs in humans. However, their data were not particu-
larly consistent or reliable because of considerable vari-
ability and the lack of any clear pattern in the types of toxic
effects. They overlooked the caveat that the absence of
toxicity in animals provided essentially no insight into the
likelihood of toxicity or absence of toxicity in humans.
Perel et al. compared treatment effects reported in sys-
tematic reviews of clinical trials with those of their own
systematic review of the corresponding animal experiments
[26]. They concluded that many animal studies are of poor
methodological quality and the lack of concordance
between animal experiments and clinical trials is the result
of bias, random error, or the failure of animal models to
adequately represent human diseases.
Although we investigated all blood cancer drugs
approved in Japan from 1999 to date, there is a limitation in
publicly available data. Access to some of the existing data
was not possible because study reports in CTD M4 and M5
were not disclosed; only summary documents, such as
CTD M2, are available. The amount of information avail-
able for different drugs varies; some CTD M2 documents
contain enough data for analysis but others do not. More-
over, as we focused on drugs for blood cancer, caution
should be taken when generalizing about drugs used in
other therapeutic areas.
We found that the potential range of applications of
nonclinical assessments in ADR predictions was substan-
tial. However, our concordance rates differed from those
reported in some other studies. Our analysis of the rela-
tionship between concordance rate and quantitative safety
profile found a weak correlation, suggesting that ADRs are
predictable on the basis of animal toxicities, especially for
some drugs with low quantitative safety profiles. Perel
et al. suggested that with the increasing number of sys-
tematic reviews of animal experiments, a quantitative
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approach to determine similarities between animal models
and clinical trials should become possible [26]. Our study
results should contribute to the development of this field.
5 Conclusion
Within the constraints of this study, our results suggest that
toxicity findings observed in animal tests could be
extrapolated to human treatments. This might allow the
prediction of ADRs in clinical trials for some drugs with a
low quantitative safety profile. Nonclinical safety assess-
ments might be useful in predicting the clinical safety of
such drugs.
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